To our knowledge, our data represent the first demonstration that CA plays an antagonistic role against ligand binding on PPARγ and, therefore, may represent a potential new class of natural compounds with known pharmacological properties in the treatment metabolic disorders. Here, PPARG is linked to metabolic disease.